Icon Plc (ICLR)
NASDAQ:ICLR
Want to see ICLR full AI Analyst Report?
Earnings Data
Report Date
Jul 29, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
2.54Last Year’s EPS
3.26Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented a mixed but stable picture: strong commercial momentum — including robust gross bookings (+22% YoY), hefty net wins (+42% YoY), higher book-to-bill (1.42x) and strategic commercial and digital initiatives — offset by notable margin compression year-over-year, pass-through volatility, and muted revenue growth on a constant currency basis. Management reiterated full-year guidance, highlighted balance sheet improvement and free cash flow generation, and outlined concrete actions and investments to drive margin recovery and long-term growth.Company Guidance
Strong Gross Bookings Growth
Gross bookings were $3.3 billion in Q1, matching Q4 2025 and up 22% year-over-year, indicating robust new business demand.
Meaningful Net Business Wins and Book-to-Bill
Net business wins totaled $2.88 billion, up 42% year-over-year, producing a net book-to-bill of 1.42x and direct-fee book-to-bill in excess of 1.3x for the quarter.
Sustained Win Rates Across Large Pharma and Biotech
Win rates remained strong and sustained the step-up seen in Q4 across both large pharma and biotech full-service businesses, with RFP flow notably improving (low double-digit sequential increase in biotech full-service).
Strategic Commercial Wins and Market Diversification
Quarter included a central labs partnership win with a top-5 pharma customer, a new midsized pharma partnership that displaced an incumbent large CRO, and broad-based bookings across therapeutic areas (oncology and cardiometabolic) with cardiometabolic awards diversified into MASH, obesity and kidney disease.
Investment in Oncology Site Network and Lab Capacity
Expanded Accellacare oncology research capabilities (partnership with Brian Moran Cancer Institute) and announced expansion of central laboratory capacity in Singapore to accelerate lab offerings and growth in Asia—steps to address patient access and geographic growth.
Innovation and AI Partnership
Announced partnership with Microsoft to build ICON's Orbis Agentic AI platform and enterprise Copilot deployments to drive efficiency, domain-specific agents and digital transformation across clinical workflows.
Revenue and EPS (Adjusted) In Line with Expectations
Reported revenue of $2.0 billion in Q1 (approximately +0.9% year-over-year reported, -1.9% constant currency) and adjusted diluted EPS of $2.50 for the quarter, with adjusted net income of $192.9 million.
Cash Generation and Balance Sheet Improvements
Q1 cash from operating activities was $167 million; capex was $30.8 million, producing free cash flow of $136.2 million. Cash totaled $765.2 million and net debt improved to $2.6 billion from $2.8 billion at year-end 2025 and $2.9 billion a year earlier, with leverage at 1.8x net debt to adjusted TTM EBITDA.
Guidance Maintained
Full-year 2026 guidance reiterated: revenue $7.85 billion to $8.15 billion and adjusted diluted EPS $10.00 to $11.00, signaling management confidence in the outlook despite near-term headwinds.
Near-Term Margin Momentum Expected
Adjusted EBITDA margin was 15.6% in Q1 (up ~10 basis points sequentially) and management expects modest sequential margin improvement through the year, guiding Q2 margin to roughly ~16% (approximately +0.5% vs Q1).
ICLR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ICLR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jun 23, 2026 | $142.67 | $158.17 | +10.86% |
May 27, 2026 | $118.45 | $136.80 | +15.49% |
Oct 22, 2025 | $192.60 | $180.00 | -6.54% |
Jul 23, 2025 | $167.89 | $195.01 | +16.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Icon Plc (ICLR) report earnings?
Icon Plc (ICLR) is schdueled to report earning on Jul 29, 2026, After Close (Confirmed).
What is Icon Plc (ICLR) earnings time?
Icon Plc (ICLR) earnings time is at Jul 29, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICLR EPS forecast?
ICLR EPS forecast for the fiscal quarter 2026 (Q2) is 2.54.